Article (Scientific journals)
Acute migraine therapy with external trigeminal neurostimulation (ACME): A randomized controlled trial
Chou, D. E.; Shnayderman Yugrakh, M.; Winegarner, D. et al.
2019In Cephalalgia, 39 (1), p. 3-14
Peer Reviewed verified by ORBi
 

Files


Full Text
Chou et al RCT acute Cefaly-Cephalalgia 2018.pdf
Publisher postprint (572.6 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Migraine
Abstract :
[en] Objective: To assess the safety and efficacy of external trigeminal nerve stimulation for acute pain relief during migraine attacks with or without aura via a sham-controlled trial. Methods: This was a double-blind, randomized, sham-controlled study conducted across three headache centers in the United States. Adult patients who were experiencing an acute migraine attack with or without aura were recruited on site and randomly assigned 1:1 to receive either verum or sham external trigeminal nerve stimulation treatment (CEFALY Technology) for 1 hour. Pain intensity was scored using a visual analogue scale (0 = no pain to 10 = maximum pain). The primary outcome measure was the mean change in pain intensity at 1 hour compared to baseline. Results: A total of 109 participants were screened between February 1, 2016 and March 31, 2017. Of these, 106 patients were randomized and included in the intention-to-treat analysis (verum: n = 52; sham: n = 54). The primary outcome measure was significantly more reduced in the verum group than in the sham group: −3.46 ± 2.32 versus −1.78 ± 1.89 (p < 0.0001), or −59% versus −30% (p < 0.0001). With regards to migraine subgroups, there was a significant difference in pain reduction between verum and sham for ‘migraine without aura’ attacks: mean visual analogue scale reduction at 1 hour was −3.3 ± 2.4 for the verum group versus −1.7 ± 1.9 for the sham group (p = 0.0006). For ‘migraine with aura’ attacks, pain reduction was numerically greater for verum versus sham, but did not reach significance: mean visual analogue scale reduction at 1 hour was −4.3 ± 1.8 for the verum group versus −2.6 ± 1.9 for the sham group (p = 0.060). No serious adverse events were reported and five minor adverse events occurred in the verum group. Conclusion: One-hour treatment with external trigeminal nerve stimulation resulted in significant headache pain relief compared to sham stimulation and was well tolerated, suggesting it may be a safe and effective acute treatment for migraine attacks. Study protocol: ClinicalTrials.gov Identifier: NCT02590939. © International Headache Society 2018.
Disciplines :
Neurology
Author, co-author :
Chou, D. E.;  Department of Neurology, Columbia University Medical Center, New York, NY, United States
Shnayderman Yugrakh, M.;  Department of Neurology, Columbia University Medical Center, New York, NY, United States
Winegarner, D.;  Rowe Neurology Institute, Lenexa, KS, United States
Rowe, V.;  Rowe Neurology Institute, Lenexa, KS, United States
Kuruvilla, D.;  Department of Neurology, Yale University School of Medicine, New Haven, CT, United States
Schoenen, Jean  ;  Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Département des sciences biomédicales et précliniques
Language :
English
Title :
Acute migraine therapy with external trigeminal neurostimulation (ACME): A randomized controlled trial
Publication date :
2019
Journal title :
Cephalalgia
ISSN :
0333-1024
eISSN :
1468-2982
Publisher :
SAGE Publications Ltd
Volume :
39
Issue :
1
Pages :
3-14
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 07 March 2021

Statistics


Number of views
58 (1 by ULiège)
Number of downloads
40 (1 by ULiège)

Scopus citations®
 
109
Scopus citations®
without self-citations
103
OpenCitations
 
101

Bibliography


Similar publications



Contact ORBi